文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

甲状腺功能减退症:综述

Hypothyroidism: A Review.
PubMed 文献 · JAMA · 2025-01-01
一句话结论左甲状腺素是甲状腺功能减退症的一线治疗,目标为促甲状腺素正常化;启动或调量后6至8周复查促甲状腺素,达标后每年监测一次。

本文综述甲状腺功能减退症的流行病学、病因、临床表现、诊断与治疗。全球患病率0.3%至12%,取决于碘摄入量,女性及老年人更常见。桥本甲状腺炎是碘营养充足地区原发性甲减的最常见病因,占高达85%。诊断依据生化检测:促甲状腺素升高且游离甲状腺素降低提示显性原发性甲减。不推荐对无症状个体筛查,推荐对高风险患者(如1型糖尿病)进行针对性检测。左甲状腺素为一线治疗,起始剂量需个体化,老年或合并房颤、冠心病者应使用较低起始剂量;启动或调量后6至8周监测促甲状腺素,达标后每年监测一次。

要点

  • 不推荐对无症状个体筛查甲减,推荐对高风险患者(如1型糖尿病)进行针对性检测。
  • 显性原发性甲减诊断依据:促甲状腺素升高且游离甲状腺素降低。
  • 左甲状腺素为一线治疗,目标为促甲状腺素正常化;老年或合并房颤、冠心病者应使用较低起始剂量。
  • 启动左甲状腺素或调量后6至8周监测促甲状腺素,达标后每年监测一次,以避免过度或不足治疗。
  • 未治疗甲减可进展为黏液性水肿昏迷,表现为低体温、低血压和意识状态改变,需ICU治疗,死亡率高达30%。

适用人群与场景

  • 全球患病率0.3%至12%,取决于碘摄入量,女性及老年人更常见。
  • 不推荐对无症状个体筛查甲减;推荐对高风险患者(如1型糖尿病)进行针对性检测。
  • 高风险因素包括:一级亲属患甲减、碘缺乏、颈部手术或放疗、妊娠合并潜在自身免疫性甲状腺病、使用某些药物(如免疫检查点抑制剂和胺碘酮)。

诊断标准与关键阈值

  • 显性原发性甲减诊断标准:促甲状腺素升高且游离甲状腺素降低。

处置流程与药物剂量

  • 一线治疗为合成左甲状腺素,目标为促甲状腺素正常化。
  • 起始剂量需根据患者特定因素个体化;老年患者或合并房颤、冠心病者应使用较低起始剂量。
  • 启动左甲状腺素治疗或改变剂量后6至8周监测促甲状腺素,达标后每年监测一次,以避免过度治疗或治疗不足。

红旗征与不能漏的情况

  • 未治疗甲减可进展为严重甲减伴失代偿(黏液性水肿昏迷),表现为低体温、低血压和意识状态改变,需在重症监护病房治疗,死亡率高达30%。

研究设计与关键结果

  • 桥本甲状腺炎(一种自身免疫病)是碘营养充足地区原发性甲减的病因,占高达85%的甲减患者。
  • 甲减症状非特异,包括疲劳(68%-83%)、体重增加(24%-59%)、认知问题(45%-48%)如记忆减退和注意力不集中、月经不规则(约23%)如月经稀发和月经过多。
  • 甲减可导致糖尿病患者胰岛素抵抗和高血糖,增加心血管事件(如心力衰竭)风险,并损害女性生殖健康,导致排卵障碍、不孕和流产风险增加。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对无症状个体不进行甲减筛查;对高风险患者(如1型糖尿病)进行针对性检测。
  • 启动左甲状腺素或调量后6至8周复查促甲状腺素,达标后每年监测一次。
  • 老年或合并房颤、冠心病者使用较低左甲状腺素起始剂量。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Hypothyroidism is a disease of thyroid hormone deficiency. The prevalence ranges from 0.3% to 12% worldwide, depending on iodine intake, and it is more common in women and older adults. Untreated hypothyroidism can cause serious health complications such as heart failure and myxedema coma.

OBSERVATIONS: Hashimoto thyroiditis (an autoimmune disease) is the cause of primary hypothyroidism in up to 85% of patients with hypothyroidism living in areas with adequate nutritional iodine levels. The risk of developing hypothyroidism is associated with genetic factors (having a first-degree relative with hypothyroidism), environmental factors (iodine deficiency), undergoing neck surgery or receiving radiation therapy, pregnancy in the setting of underlying autoimmune thyroid disease, and with the use of certain medications (eg, immune checkpoint inhibitors and amiodarone). Patients with hypothyroidism may have nonspecific symptoms due to metabolic slowing, including fatigue (68%-83%), weight gain (24%-59%), cognitive issues (45%-48%) such as memory loss and difficulty concentrating, and menstrual irregularities (approximately 23%) such as oligomenorrhea and menorrhagia. Hypothyroidism can cause insulin resistance and hyperglycemia in patients with diabetes, increase the risk for cardiovascular events, such as heart failure, and negatively affect female reproductive health, causing disrupted ovulation, infertility, and increased risk of miscarriage. Untreated hypothyroidism may progress to severe hypothyroidism with decompensation (myxedema coma), which is a condition associated with hypothermia, hypotension, and altered mental status that requires treatment in an intensive care unit and has a mortality rate of up to 30%. Hypothyroidism is diagnosed based on biochemical testing; a high thyrotropin (TSH) level and a low free thyroxine (T4) level indicate overt primary hypothyroidism. Screening for hypothyroidism is not recommended for asymptomatic individuals. Targeted testing is recommended for patients who are considered high risk (eg, patients with type 1 diabetes). First-line treatment for hypothyroidism is synthetic levothyroxine to normalize thyrotropin levels. Initial dosages should be tailored to patient-specific factors. Lower starting doses should be used for older patients or those with atrial fibrillation and coronary artery disease. Thyrotropin monitoring should be performed 6 to 8 weeks after initiating levothyroxine treatment, or when changing the dose, and then annually once the thyrotropin level is at goal to avoid overtreatment or undertreatment, both of which are associated with cardiovascular health risks.

CONCLUSIONS AND RELEVANCE: Hypothyroidism may be associated with fatigue, weight gain, memory loss, difficulty concentrating, cardiovascular disease such as heart failure, menstrual irregularities, infertility, and increased risk of miscarriage. Levothyroxine is the first-line treatment to normalize the thyrotropin level and improve clinical manifestations due to hypothyroidism.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Chaker L, Papaleontiou M. Hypothyroidism: A Review. JAMA. 2025. PMID: 40900603. doi:10.1001/jama.2025.13559

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。